Trial Profile
Serial Fecal Microbiota Transplant (FMT) Plus Fidaxomicin in the Treatment of Severe or Fulminant Clostridium Difficile Infection, With Detailed Characterization in Microbiota, Metabolomics and Host Immune Response
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 12 Aug 2022 Status changed from completed to discontinued.
- 01 Apr 2022 Status changed from recruiting to completed.
- 26 Jun 2019 Planned primary completion date changed from 16 Dec 2020 to 16 Dec 2021.